Oncology
Daraxonrasib Adds a Metastatic Pancreatic Cancer Option
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma after systemic therapy or when multi-agent therapy is not feasible.
Rayan Salih · September 4, 2026 · 6 min